Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBRUNONI, Andre R.
dc.contributor.authorMACHADO-VIEIRA, Rodrigo
dc.contributor.authorSAMPAIO-JUNIOR, Bernardo
dc.contributor.authorVIEIRA, Erica L. M.
dc.contributor.authorVALIENGO, Leandro
dc.contributor.authorBENSENOR, Isabela M.
dc.contributor.authorLOTUFO, Paulo A.
dc.contributor.authorCARVALHO, Andre F.
dc.contributor.authorCHO, Hyong Jin
dc.contributor.authorGATTAZ, Wagner F.
dc.contributor.authorTEIXEIRA, Antonio L.
dc.date.accessioned2015-10-26T16:25:10Z
dc.date.available2015-10-26T16:25:10Z
dc.date.issued2015
dc.description.abstractBackground: The cytokine hypothesis of depression postulates that the pathophysiology of this illness incorporates an increased production of pro-inflammatory cytokines, which leads to an over activation of the hypothalamic-pituitary-adrenal axis as well as monoaminergic disturbances. Nevertheless, it remains unclear whether the amelioration of depressive symptoms could decrease cytokine levels. Notwithstanding antidepressant drug therapy might exert anti-inflammatory effects, the effects of non-invasive neuromodulatory approaches like transcranial direct current stimulation (tDCS) on pro-inflammatory cytokine networks are largely unknown. Methods: We evaluated, in the Set-Leanne vs. Eleciric Curreni Therapy for TreaLing Depression Clinical SLudy (SELECT-TDCS) fetal, whether the plasma levels of the soluble TNF recepLors 1 and 2 (sTNFRs) changed tiller anLiclepressanL LreaLmeni in a sample of 73 anLidepressanL-free paLienis with unipolar depressive disorder in an episode of aL leasL mocleraLe inLensiLy. Results: Although boat LDCS and set-Leanne exerLed anLiclepressanL effecfs. the plasma levels of sTNFRs did noi change over Lime regardless of Lhe infervenLion and clinical response. Also, baseline sTNFRs levels did noL predicL anLiclepressanL response. Limitations: Our negative findings could be a type LI error, as this trial did not use an equivalence design. Conclusions: To conclude, in this novel placebo-controlled trial prospectively evaluating the changes of sTNFRs in depressed patients, we found that these molecules are not surrogate biomarkers of treatment I esponse of tDCS, whose antidepressant effects occurred regardless of normalization of immunological activity.
dc.description.indexMEDLINE
dc.description.sponsorshipFAPESP (Sao Paulo Research Foundation) [2009/05728-7]
dc.description.sponsorshipFAPEMIG
dc.description.sponsorshipCNPq
dc.identifier.citationJOURNAL OF AFFECTIVE DISORDERS, v.185, p.209-213, 2015
dc.identifier.doi10.1016/j.jad.2015.07.006
dc.identifier.eissn1573-2517
dc.identifier.issn0165-0327
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/11549
dc.language.isoeng
dc.publisherELSEVIER SCIENCE BV
dc.relation.ispartofJournal of Affective Disorders
dc.rightsrestrictedAccess
dc.rights.holderCopyright ELSEVIER SCIENCE BV
dc.subjectMajor depressive disorder
dc.subjectTranscranial direct current sdmulation
dc.subjectSertraline
dc.subjectSTNFR1
dc.subjectSTNFR2
dc.subject.otherelectrical-current therapy
dc.subject.otherantidepressant treatment
dc.subject.othercytokine production
dc.subject.othermetaanalysis
dc.subject.otherdisorder
dc.subject.otherfactorial
dc.subject.otheril-6
dc.subject.otherpathways
dc.subject.otherimpact
dc.subject.wosClinical Neurology
dc.subject.wosPsychiatry
dc.titlePlasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalMACHADO-VIEIRA, Rodrigo:NIMH, Expt Therapeut & Pathophysiol Branch, Intramural Res Program, NIH, Bethesda, MD 20892 USA
hcfmusp.author.externalVIEIRA, Erica L. M.:Fed Univ Minas Gerais UFMG, Sch Med, Interdisciplinary Lab Med Invest LIIM, Div Neurosci, Belo Horizonte, MG, Brazil
hcfmusp.author.externalCARVALHO, Andre F.:Univ Fed Ceara, Dept Clin Med, Fortaleza, Ceara, Brazil; Univ Fed Ceara, Translat Pychiatry Res Grp, Fac Med, Fortaleza, Ceara, Brazil
hcfmusp.author.externalCHO, Hyong Jin:Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA 90024 USA
hcfmusp.citation.scopus18
hcfmusp.contributor.author-fmusphcANDRE RUSSOWSKY BRUNONI
hcfmusp.contributor.author-fmusphcBERNARDO DE SAMPAIO PEREIRA JUNIOR
hcfmusp.contributor.author-fmusphcLEANDRO DA COSTA LANE VALIENGO
hcfmusp.contributor.author-fmusphcISABELA JUDITH MARTINS BENSEñOR
hcfmusp.contributor.author-fmusphcPAULO ANDRADE LOTUFO
hcfmusp.contributor.author-fmusphcWAGNER FARID GATTAZ
hcfmusp.description.beginpage209
hcfmusp.description.endpage213
hcfmusp.description.volume185
hcfmusp.origemWOS
hcfmusp.origem.pubmed26241865
hcfmusp.origem.scopus2-s2.0-84938319315
hcfmusp.origem.wosWOS:000359725400030
hcfmusp.publisher.cityAMSTERDAM
hcfmusp.publisher.countryNETHERLANDS
hcfmusp.relation.referenceBrunoni A. R., 2013, INT J NEUROPSYCHOPHA
hcfmusp.relation.referenceBrunoni AR, 2013, JAMA PSYCHIAT, V70, P383, DOI 10.1001/2013.jamapsychiatry.32
hcfmusp.relation.referenceBrunoni AR, 2011, CONTEMP CLIN TRIALS, V32, P90, DOI 10.1016/j.cct.2010.09.007
hcfmusp.relation.referenceBrunoni AR, 2014, PSYCHOPHARMACOLOGY, V231, P1315, DOI 10.1007/s00213-013-3322-3
hcfmusp.relation.referenceBrunoni AR, 2014, EUR NEUROPSYCHOPHARM, V24, P1144, DOI 10.1016/j.euroneuro.2014.03.006
hcfmusp.relation.referenceBrunoni AR, 2014, PROG NEUROPSYCHOPH C, V56C, P91
hcfmusp.relation.referenceDean B, 2013, MOL PSYCHIATR, V18, P767, DOI 10.1038/mp.2012.95
hcfmusp.relation.referenceDellaGioia N, 2010, NEUROSCI BIOBEHAV R, V34, P130, DOI 10.1016/j.neubiorev.2009.07.014
hcfmusp.relation.referenceFornaro M, 2013, J AFFECT DISORDERS, V145, P300, DOI 10.1016/j.jad.2012.08.007
hcfmusp.relation.referenceGrassi-Oliveira R, 2009, PSYCHIAT CLIN NEUROS, V63, P202, DOI 10.1111/j.1440-1819.2008.01918.x
hcfmusp.relation.referenceHannestad J, 2011, NEUROPSYCHOPHARMACOL, V36, P2452, DOI 10.1038/npp.2011.132
hcfmusp.relation.referenceHowren MB, 2009, PSYCHOSOM MED, V71, P171, DOI 10.1097/PSY.0b013e3181907c1b
hcfmusp.relation.referenceKohler O, 2014, JAMA PSYCHIAT, V71, P1381, DOI 10.1001/jamapsychiatry.2014.1611
hcfmusp.relation.referenceLanquillon S, 2000, NEUROPSYCHOPHARMACOL, V22, P370, DOI 10.1016/S0893-133X(99)00134-7
hcfmusp.relation.referenceMaes M, 2011, PROG NEURO-PSYCHOPH, V35, P769, DOI 10.1016/j.pnpbp.2010.06.008
hcfmusp.relation.referenceMueller N, 2007, MOL PSYCHIATR, V12, P988, DOI 10.1038/sj.mp.4002006
hcfmusp.relation.referenceMunzer A, 2013, TOXINS, V5, P2227, DOI 10.3390/toxins5112227
hcfmusp.relation.referenceRaison CL, 2013, JAMA PSYCHIAT, V70, P31, DOI 10.1001/2013.jamapsychiatry.4
hcfmusp.relation.referenceTeixeira AL, 2015, HUM PSYCHOPHARM CLIN, V30, P52, DOI 10.1002/hup.2450
hcfmusp.relation.referenceValkanova V, 2013, J AFFECT DISORDERS, V150, P736, DOI 10.1016/j.jad.2013.06.004
hcfmusp.relation.referenceWajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189
hcfmusp.relation.referenceXia ZL, 1996, IMMUNOPHARMACOLOGY, V34, P27, DOI 10.1016/0162-3109(96)00111-7
hcfmusp.relation.referenceYoung JJ, 2014, J AFFECT DISORDERS, V169, P15, DOI 10.1016/j.jad.2014.07.032
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication7d074e1c-d01c-47ef-a563-4fc4444a8219
relation.isAuthorOfPublication253a63b5-54d7-4c7f-940d-58f11a4795d8
relation.isAuthorOfPublicationf3cdfded-0cdb-4fba-9a19-b0be89301c89
relation.isAuthorOfPublication6911f59e-7ec9-4ad2-b746-580bf8b3d64d
relation.isAuthorOfPublicationcb0c8dbb-6df5-4294-8d8e-e96645a3cec1
relation.isAuthorOfPublication125dcc9f-a05a-42fd-ab1d-b6db35d2616b
relation.isAuthorOfPublication.latestForDiscovery7d074e1c-d01c-47ef-a563-4fc4444a8219
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_BRUNONI_Plasma_levels_of_soluble_TNF_receptors_1_and_2015.PDF
Tamanho:
330.25 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - LIM/27
Artigos e Materiais de Revistas Científicas - ODS/03